Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

XenaCare merging with Sun Packing

This article was originally published in The Tan Sheet

Executive Summary

Delray Beach, Fla.-based nutritional product firm XenaCare Holdings, which is launching the SunPill supplement designed to help protect skin, announced Aug. 22 it filed with the Securities and Exchange Commission to merge with Houston -based Sun Packing. Through the deal expected to close by October, XenaCare says it will put Sun Packing in charge of 50.1 percent of shares in the merged company. The merger "will reflect a combined business entity with expected first year sales in excess of $15 million and the capability" to apply for NASDAQ or American Stock Exchange Listing, says XenaCare President Frank Rizzo. XenaCare says a new name reflecting both businesses may be developed

You may also be interested in...



OTC Drug Oversight By US FDA Split Among Two Divisions In Reorganization

CDER Office of New Drugs changes its organization including establishing Office of Nonprescription Drugs and splitting the office into Division of Nonprescription Drug Products I and DNDP II. A Division of Regulatory Operations for Nonprescription Drugs will be comprised of regulatory staff from the ONPD divisions and will report to OND’s regulatory office. Non-clinical ONPD staff will report to the office director.

Verrica Ready To Target Pediatric Dermatologists With First Molluscum Therapy

Anticipating a July approval of its cantharidin formulation, Verrica says it is poised to implement a buy-and-bill model for a clinician-administered product with an addressable market of 6 million.

Price Inflation Rebates And The Spectre Of 100% Discounts In Medicare Part D

Medicaid programs are essentially getting Humira for free, in large part because of price inflation rebates, according to estimates by Bernstein analysts. Legislation pending in the US Senate wants to bring that dynamic to Medicare.

Topics

UsernamePublicRestriction

Register

PS102040

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel